Biomea Fusion, Inc. Revenue Breakdown
No Revenue Breakdown for BMEA on this site yet.
- 2022-09-30: Others Not split by product$165.00M100.00%; Total revenue $165.00M.
- 2022-06-30: Others Not split by product$0.00; Total revenue $0.00.
- 2022-03-31: Others Not split by product$1.07B100.00%; Total revenue $1.07B.
- 2021-09-30: Others Not split by product$0.00; Total revenue $0.00.
Source checked: the stored Revenue Breakdown page for BMEA.
Revenue by product
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2022-09-30 | Not split by product $165.00M 100.00% | $165.00M |
| 2022-06-30 | Not split by product $0.00 | $0.00 |
| 2022-03-31 | Not split by product $1.07B 100.00% | $1.07B |
| 2021-09-30 | Not split by product $0.00 | $0.00 |
| 2021-06-30 | Not split by product $0.00 | $0.00 |
| 2021-03-31 | Not split by product $1.07B 100.00% | $1.07B |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |